
Central Nervous System Biomarkers Market Share
Central Nervous System Biomarkers Market Research Report Information by Type Procedure (Safety, Efficacy, Validation Biomarker), Application (Drug Discovery & Development, Personalized Medicine), End Use (Diagnostic Labs, Hospitals & Clinics, Research Centers), and Region (North America, Europe, Asia-Pacific, Rest of the World)—Forecast to 2035

Market Summary
The Global Central Nervous System Biomarkers Market is projected to grow significantly from 6.5 USD Billion in 2024 to 15.7 USD Billion by 2035.
Key Market Trends & Highlights
Central Nervous System Biomarkers Key Trends and Highlights
- The market is expected to expand at a compound annual growth rate of 8.35 percent from 2025 to 2035.
- By 2035, the market valuation is anticipated to reach 15.7 USD Billion, indicating robust growth potential.
- In 2024, the market is valued at 6.5 USD Billion, reflecting the increasing focus on neurological disorders.
- Growing adoption of advanced diagnostic technologies due to the rising prevalence of neurological diseases is a major market driver.
Market Size & Forecast
2024 Market Size | 6.5 (USD Billion) |
2035 Market Size | 15.7 (USD Billion) |
CAGR (2025-2035) | 8.35% |
Largest Regional Market Share in 2024 | latin_america) |
Major Players
Thermo Fisher Scientific (US), Merck & Co. (US), AbaStarMDx Inc. (US), Abiant, Inc. (US), Avacta Group plc (UK), Diagenic Asa (Norway), Banyan Biomarkers (US), Avid Radiopharmaceuticals Inc. (US), Acumen pharmaceuticals Inc. (US), Siemens AG (Germany), Novartis (Switzerland)
Market Trends
The increasing prevalence of neurological disorders is driving the demand for innovative biomarkers that can facilitate early diagnosis and personalized treatment strategies in the Central Nervous System sector.
National Institute of Neurological Disorders and Stroke (NINDS)
Central Nervous System Biomarkers Market Market Drivers
Rising Prevalence of Neurological Disorders
The increasing incidence of neurological disorders such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis drives the Global Central Nervous System Biomarkers Market Industry. As the global population ages, the prevalence of these conditions is expected to rise significantly. For instance, the World Health Organization indicates that by 2030, the number of individuals aged 60 years and older will reach 1.4 billion, highlighting the urgent need for effective diagnostic tools. This growing demand for biomarkers to aid in early diagnosis and treatment monitoring is projected to contribute to the market's growth, with an estimated value of 6.5 USD Billion in 2024.
Market Segment Insights
Regional Insights
Key Companies in the Central Nervous System Biomarkers Market market include






Industry Developments
- InSeptember 2020, Siemens Healthineersannounced a strategic collaboration with Novartis Pharma AG for biomarker development for Multiple Sclerosis.
- In May 2019, N170 CNS biomarker letter of intent submitted by Roche (Switzerland) was accepted by FDA for autism spectrum disorder.
- In March 2020, Oculomotor Index was accepted by FDA as a valid biomarker for the diagnosis of autism spectrum disorder, submitted by The Autism Biomarkers Consortium for Clinical Trials (ABC-CT).
Future Outlook
Central Nervous System Biomarkers Market Future Outlook
The Central Nervous System Biomarkers Market is projected to grow at an 8.35% CAGR from 2024 to 2035, driven by advancements in diagnostics, increasing prevalence of neurological disorders, and rising demand for personalized medicine.
New opportunities lie in:
- Develop innovative biomarker-based diagnostic tools for early detection of neurodegenerative diseases.
- Invest in AI-driven analytics platforms to enhance biomarker discovery and validation processes.
- Forge strategic partnerships with pharmaceutical companies to integrate biomarkers in clinical trials.
By 2035, the Central Nervous System Biomarkers Market is expected to reach substantial growth, reflecting evolving healthcare needs and technological advancements.
Market Segmentation
Report Overview:
Central Nervous System Biomarkers Market Segmentation
- {"Safety Biomarker"=>[]}
- {"Diagnostic Labs"=>[]}
- {"Drug Discovery & Development"=>[]}
- {"North America"=>[]}
Report Scope
Report Attribute/Metric | Details |
Market Size 2023 | 6.01 (USD Billion) |
Market Size 2024 | 6.50 (USD Billion) |
Market Size 2032 | 12.24 (USD Billion) |
Compound Annual Growth Rate (CAGR) | 8.67 % (2024 - 2032) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Base Year | 2023 |
Market Forecast Period | 2024 - 2032 |
Historical Data | 2019 - 2023 |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Thermo fisher scientific (US), Merck & Co (US), AbaStarMDx Inc (US), Abiant, Inc (US), Avacta Group Plc (UK), Diagenic Asa (Norway), Banyan Biomarkers (US), Avid Radiopharmaceuticals Inc (US), Acumen pharmaceuticals Inc (US) and others |
Key Market Opportunities | Untapped APAC region have significant opportunity for CNS biomarker market and rising |
Key Market Drivers | New technological advancements and their increased use in the diagnosis of neurodegenerative diseases Increase in R&D for new CNS biomarkers and successful clinical trials |
Market Highlights
Author
Latest Comments
This is a great article! Really helped me understand the topic better.
Thanks for sharing this. I’ve bookmarked it for later reference.
FAQs
What is the valuation of the Central Nervous System Biomarkers Market?
central nervous system biomarkers market is reachinga market value of USD ~12.24 Billion by 2032
What is the growth rate of the Central Nervous System Biomarkers Market?
central nervous system biomarkers market is expected to record a CAGR of ~8.67% during the forecast period 2024-2032
What are the factors driving the Central Nervous System Biomarkers Market?
The major factors driving the CNS biomarkers market include new technological advancements and their increased use in the diagnosis of neurodegenerative diseases. Moreover, an increase in R&D for new CNS biomarkers and successful clinical trials further contribute to the market growth.
What is the leading regional Central Nervous System Biomarkers Market?
North America is expected to dominate the CNS biomarkers market in 2021, owing to the growing geriatric population, the adoption of the latest technologies for CNS disorder treatment, and key industry players across the region.
Who are the major players in the Central Nervous System Biomarkers Market?
Some of the key players in the CNS biomarkers market are Thermo Fisher Scientific (US), Merck & Co. (US), AbaStarMDx Inc. (US), Abiant, Inc. (US), Avacta Group plc (UK), Diagenic Asa (Norway), Banyan Biomarkers (US), Avid Radiopharmaceuticals Inc. (US), and Acumen Pharmaceuticals Inc. (US) amongothers.
-
Table of Contents
-
EXCECUTIVE SUMMARY
-
Market Introduction
- Definition
-
Scope of the Study
- Research Objective
- Assumptions
- Limitations
-
Research Methodology
- Overview
- Data Mining
- Secondary Research
-
Primary Research
- Primary Interviews and Information Gathering Process
- Breakdown of Primary Respondents
- Forecasting Application
-
Market Size Estimation
- Bottom-up Approach
- Top-Down Approach
- Data Triangulation
- Validation
-
MARKET DYNAMICS
- Overview
- Drivers
- Restraints
- Opportunities
-
MARKET FACTOR ANALYSIS
-
Porter’s Five Forces Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of New Entrants
- Threat of Substitutes
- Intensity of Rivalry
- Value Chain Analysis
-
COVID-19 Impact Analysis
- Market Impact Analysis
- Impact on Supply Chain
- Regional Impact
- Opportunity and Threat Analysis
-
Porter’s Five Forces Analysis
-
GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE
- Overview
- Safety Biomarker
- Efficacy Biomarker
- Validation Biomarker
- Others
-
GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION
- Overview
- Drug Discovery & Development
- Personalized Medicine
- Others
-
GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USE
- Overview
- Diagnostic Labs
- Clinics/Hospitals
- Research Centers
-
GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY REGION
- Overview
-
North America
- US
- Canada
-
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
-
Asia-Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia-Pacific
-
Rest of the World
- Middle East
- Africa
- Latin America
-
COMPANY LANDSCAPE
- Overview
- Competitive Analysis
- Market Share Analysis
- Major Growth Strategy in the Global Central Nervous System Biomarkers Market
- Competitive Benchmarking
- Leading Players in terms of Number of Developments in the Global Central Nervous System Biomarkers Market
-
Key Developments and Growth Strategies
- New ProductLaunch/Service Deployment
- Merger &Acquisitions
- Joint Ventures
-
Major Players Financial Matrix
- Sales & Operating Income, 2020
- Major Players R&D Expenditure, 2020
-
COMPANY PROFILES
-
Thermo Fisher Scientific (US)
- Company Overview
- Financial Overview
- Products Offered
- Key Developments
- SWOT Analysis
- Key Strategies
- Merck & Co (US)
- AbaStar MDx Inc (US)
- Abiant, Inc (US)
- Avacta Group Plc (UK)
- Diagenic Asa (Norway)
- Banyan Biomarkers (US)
- Avid Radiopharmaceuticals Inc (US)
- Acumen pharmaceuticals Inc (US)
- Siemens AG (Germany)
- Novartis (Switzerland)
- Others
-
Thermo Fisher Scientific (US)
-
APPENDIX
- References
- Related Reports
-
-
List of Tables and Figures
- LIST OF TABLES
- TABLE 1 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SYNOPSIS, 2018–2027
- TABLE 2 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET ESTIMATES & FORECAST, 2018–2027 (USD MILLION)
- TABLE 3 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 4 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
- TABLE 5 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)
- TABLE 6 NORTH AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 7 NORTH AMERICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
- TABLE 8 NORTH AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)
- TABLE 9 US: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 10 US CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
- TABLE 11 US: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)
- TABLE 12 CANADA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 13 CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
- TABLE 14 CANADA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)
- TABLE 15 EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 16 EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
- TABLE 17 EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)
- TABLE 18 GERMANY: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 19 GERMANY: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
- TABLE 20 GERMANY: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)
- TABLE 21 FRANCE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 22 FRANCE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
- TABLE 23 FRANCE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)
- TABLE 24 ITALY: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 25 ITALY: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
- TABLE 26 ITALY: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)
- TABLE 27 SPAIN: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 28 SPAIN: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
- TABLE 29 SPAIN: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)
- TABLE 30 UK: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 31 UK: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
- TABLE 32 UK: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)
- TABLE 33 REST OF EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 34 REST OF EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
- TABLE 35 REST OF EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)
- TABLE 36 ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 37 ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
- TABLE 38 ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)
- TABLE 39 JAPAN: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 40 JAPAN: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
- TABLE 41 JAPAN: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)
- TABLE 42 CHINA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 43 CHINA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
- TABLE 44 CHINA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)
- TABLE 45 INDIA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 46 INDIA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
- TABLE 47 INDIA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)
- TABLE 48 AUSTRALIA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 49 AUSTRALIA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, APPLICATION, 2018–2027 (USD MILLION)
- TABLE 50 AUSTRALIA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, END USER, 2018–2027 (USD MILLION)
- TABLE 51 SOUTH KOREA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 52 SOUTH KOREA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, APPLICATION, 2018–2027 (USD MILLION)
- TABLE 53 SOUTH KOREA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, END USER, 2018–2027 (USD MILLION)
- TABLE 54 REST OF ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 55 REST OF ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY APPLICATION, 2018–2027 (USD MILLION)
- TABLE 56 REST OF ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY END USER, 2018–2027 (USD MILLION)
- TABLE 57 REST OF THE WORLD: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 58 REST OF THE WORLD: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, APPLICATION 2018–2027 (USD MILLION)
- TABLE 59 REST OF THE WORLD: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, END USER, 2018–2027 (USD MILLION)
- TABLE 60 MIDDLE EAST: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 61 MIDDLE EAST: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, APPLICATION 2018–2027 (USD MILLION)
- TABLE 62 MIDDLE EAST: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, END USER, 2018–2027 (USD MILLION)
- TABLE 63 AFRICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 64 AFRICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, APPLICATION 2018–2027 (USD MILLION)
- TABLE 65 AFRICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, END USER, 2018–2027 (USD MILLION)
- TABLE 66 LATIN AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, BY TYPE, 2018–2027 (USD MILLION)
- TABLE 67 LATIN AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, APPLICATION 2018–2027 (USD MILLION)
- TABLE 68 LATIN AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, END USER, 2018–2027 (USD MILLION) LIST OF FIGURES
- FIGURE 1 RESEARCH PROCESS
- FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET
- FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET
- FIGURE 4 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY TYPE, 2020 (%)
- FIGURE 5 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY APPLICATION, 2020 (%)
- FIGURE 6 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY END USER, 2020 (%)
- FIGURE 7 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%)
- FIGURE 8 NORTH AMERICA: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%)
- FIGURE 9 EUROPE: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%)
- FIGURE 10 ASIA-PACIFIC: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%)
- FIGURE 11 REST OF THE WORLD: CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY REGION, 2020 (%)
- FIGURE 12 GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)
- FIGURE 13 THERMO FISHER SCIENTIFIC: KEY FINANCIALS
- FIGURE 14 THERMO FISHER SCIENTIFIC: SEGMENTAL REVENUE
- FIGURE 15 THERMO FISHER SCIENTIFIC: REGIONAL REVENUE
- FIGURE 16 MERCK & CO.: KEY FINANCIALS
- FIGURE 17 MERCK & CO.: SEGMENTAL REVENUE
- FIGURE 18 MERCK & CO.: REGIONAL REVENUE
- FIGURE 19 ABASTAR MDX INC.: KEY FINANCIALS
- FIGURE 20 ABASTAR MDX INC..: SEGMENTAL REVENUE
- FIGURE 21 ABASTAR MDX INC.: REGIONAL REVENUE
- FIGURE 22 ABIANT, INC.: KEY FINANCIALS
- FIGURE 23 ABIANT, INC.: SEGMENTAL REVENUE
- FIGURE 24 ABIANT, INC.: REGIONAL REVENUE
- FIGURE 25 AVACTA GROUP PLC: KEY FINANCIALS
- FIGURE 26 AVACTA GROUP PLC: SEGMENTAL REVENUE
- FIGURE 27 AVACTA GROUP PLC: REGIONAL REVENUE
- FIGURE 28 DIAGENIC ASA: KEY FINANCIALS
- FIGURE 29 DIAGENIC ASA: SEGMENTAL REVENUE
- FIGURE 30 DIAGENIC ASA: REGIONAL REVENUE
- FIGURE 31 BANYAN BIOMARKERS: KEY FINANCIALS
- FIGURE 32 BANYAN BIOMARKERS: SEGMENTAL REVENUE
- FIGURE 33 BANYAN BIOMARKERS: REGIONAL REVENUE
- FIGURE 34 AVID RADIOPHARMACEUTICALS INC.: KEY FINANCIALS
- FIGURE 35 AVID RADIOPHARMACEUTICALS INC.: SEGMENTAL REVENUE
- FIGURE 36 AVID RADIOPHARMACEUTICALS INC.: REGIONAL REVENUE
- FIGURE 37 ACUMEN PHARMACEUTICALS INC.: KEY FINANCIALS
- FIGURE 38 ACUMEN PHARMACEUTICALS INC.: SEGMENTAL REVENUE
- FIGURE 39 ACUMEN PHARMACEUTICALS INC.: REGIONAL REVENUE
- FIGURE 40 SIEMENS AG: KEY FINANCIALS
- FIGURE 41 SIEMENS AG: SEGMENTAL REVENUE
- FIGURE 42 SIEMENS AG: REGIONAL REVENUE
- FIGURE 43 NOVARTIS AG: KEY FINANCIALS
- FIGURE 44 NOVARTIS AG: SEGMENTAL REVENUE
- FIGURE 45 NOVARTIS AG: REGIONAL REVENUE
Central Nervous System Biomarkers Market Segmentation
Market Segmentation Overview
- Detailed segmentation data will be available in the full report
- Comprehensive analysis by multiple parameters
- Regional and country-level breakdowns
- Market size forecasts by segment

Free Sample Request
Kindly complete the form below to receive a free sample of this Report
Customer Strories
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Leave a Comment